Congrès Targeted Anticancer Therapies — TAT 2015

The TAT (Targeted Anticancer Therapies) Congress Conference was held in Paris, March 2–4 2015. Once again immunotherapy had the place of honor with PD-1/PD-L1 inhibitors, CSF-1 receptor inhibitor, adoptive immunotherapy, and development of combinations. The challenge is to identify the patients who could best respond to the immunotherapies. Among other drugs of interest, we can name cyclin-dependant kinase inhibitors or DNA methylation targeting drugs as well as PARP inhibitors or ATR inhibitors. Finally, a third generation of tyrosine-kinase inhibitors (TKI) is being assessed to overcome acquired resistance to the first TKI; such as rociletinib for lung cancer with T790M mutation. Molecular screening has proved its benefit in clinic routine with the MOSCATO-01 trial results; and new radiological and radiomic criteria are being validated to evaluate the tumoral response for patients who are treated by immunotherapy or targeted therapies.